Background
SCH-527123 is a novel, selective CXC chemokine receptor 2 (CXCR2) antagonist.
SCH-527123 was able to suppress CXCR2-mediated signal transduction as shown through decreased phosphorylation of the NF-κB/mitogen-activated protein kinase (MAPK)/AKT pathway [1].?
Cells were treated with increasing concentrations of SCH-527123 for 72 hours and showed dose-dependent growth inhibitory activity with IC50 (72 h) values ranging from 18 to 40 μmol/L. Importantly the IL-8–overexpressing cells showed a higher IC50 (72 h) concentration of SCH-527123 than parental cells [HCT116 and E2 (P < 0.005): 28.9 ± 0.02 μmol/L and 39.5 ± 0.01 μmol/L, respectively; Caco2 and IIIe (P < 0.005): 18.8 ± 0.03 μmol/L and 25.5 ± 0.02 μmol/L, respectively]. Therefore, SCH-527123 decreased growth inhibitory activity in colorectal cancer cell lines [2].
参考文献
参考文献:
[1]. Holz O, Khalilieh S, Ludwig-Sengpiel A et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Holz O1, Khalilieh S, Ludwig-Sengpiel A et al.
[2]. Holz O1, Khalilieh S, Ludwig-Sengpiel A et al. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther. 2012 Jun;11(6):1353-64.
Protocol
|
Cell experiment[1]:
|
|
Cell lines
|
Human melanoma cell line (A375SM )
|
|
Preparation method
|
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
|
|
Reaction Conditions
|
1 μg/ml, 72h
|
|
Applications
|
SCH-479833 or SCH 527123 inhibited the melanoma cell proliferation, chemotaxis, and invasive potentialin vitro.Treatment of melanoma cells with SCH-479833 or SCH 527123 also inhibited tumor growth. Histologic and histochemical analyses showed significant (P<0.05) decreases in tumor cell proliferation and microvessel density in tumors. Moreover, we observed a significant increase in melanoma cell apoptosis in SCH-479833- or SCH 527123-treated animals compared with controls.
|
|
Animal experiment[1]:
|
|
Animal models
|
Male BALB/c mice, 20-25 g
|
|
Dosage form
|
Sch-527123 was suspended in 0.4% methylcellulose
|
|
Applications
|
Sch 527123 was bound with high affinity to the CXCR2 receptors of mouse (Kd=0.20 nM), rat (Kd=0.20 nM), and cynomolgus monkey (Kd=0.08 nM) and was a potent antagonist of CXCR2-mediated chemotaxis (IC50~3– 6 nM). In contrast, Sch 527123 bound to cynomolgus CXCR1 with lesser affinity (Kd=41 nM) and weakly inhibited cynomolgus CXCR1-mediated chemotaxis (IC50 ~1000 nM). Oral treatment with Sch-527123 blocked pulmonary neutrophilia (ED50=1.2 mg/kg) and goblet cell hyperplasia (32–38% inhibition at 1–3 mg/kg) in mice following the intranasal lipopolysaccharide (LPS) administration. In rats, Sch-527123 suppressed the pulmonary neutrophilia (ED=501.8 mg/kg) and increase in bronchoalveolar lavage (BAL) mucin content (ED 50≤ 0.1 mg/kg) induced by intratracheal (i.t.) LPS. Sch-527123 also suppressed the pulmonary neutrophilia (ED50=1.3 mg/kg), goblet cell hyperplasia (ED 50=0.7 mg/kg), and increase in BAL mucin content (ED50<1 mg/kg) in rats after i.t. administration of vanadium pentoxide. In cynomolgus monkeys, Sch-527123 reduced the pulmonary neutrophilia induced by repeat bronchoscopy and lavage (ED50=0.3 mg/kg).
|
|
Other notes
|
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
|
|
参考文献:
1. Singh S1, Sadanandam A, Nannuru KC et al. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res. 2009 Apr 1;15(7):2380-6.
2. Chapman RW1, Minnicozzi M, Celly CS et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther. 2007 Aug;322(2):486-93. Epub 2007 May 11.
|
没有评价数据